Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Lineage Plasticity in Cancer Progression and Treatment.

Le Magnen C, Shen MM, Abate-Shen C.

Annu Rev Cancer Biol. 2018 Mar;2:271-289. doi: 10.1146/annurev-cancerbio-030617-050224. Epub 2017 Dec 1.

PMID:
29756093
2.

Prostate Cancer Metastasis - Fueled by Fat?

Abate-Shen C.

N Engl J Med. 2018 Apr 26;378(17):1643-1645. doi: 10.1056/NEJMcibr1800808. No abstract available.

PMID:
29694822
3.

Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

Arriaga JM, Abate-Shen C.

Cold Spring Harb Perspect Med. 2018 Apr 16. pii: a030528. doi: 10.1101/cshperspect.a030528. [Epub ahead of print]

PMID:
29661807
4.

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.

Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, Chua CW, Barlow LJ, Kandoth C, Williams AB, Bergren SK, Pietzak EJ, Anderson CB, Benson MC, Coleman JA, Taylor BS, Abate-Shen C, McKiernan JM, Al-Ahmadie H, Solit DB, Shen MM.

Cell. 2018 Apr 5;173(2):515-528.e17. doi: 10.1016/j.cell.2018.03.017.

PMID:
29625057
5.

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.

Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, Le Magnen C, Chester D, Mostaghel EA, Califano A, Rubin MA, Shen MM, Abate-Shen C.

Cancer Discov. 2017 Jul;7(7):736-749. doi: 10.1158/2159-8290.CD-16-1174. Epub 2017 Apr 14.

6.

Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.

Dutta A, Panja S, Virk RK, Kim JY, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JM, Mostaghel EA, Barbieri CE, Mitrofanova A, Abate-Shen C.

Eur Urol. 2017 Oct;72(4):499-506. doi: 10.1016/j.eururo.2017.03.031. Epub 2017 Apr 4.

PMID:
28385453
7.

ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.

Owczarek TB, Kobayashi T, Ramirez R, Rong L, Puzio-Kuter AM, Iyer G, Teo MY, Sánchez-Vega F, Wang J, Schultz N, Zheng T, Solit DB, Al-Ahmadie HA, Abate-Shen C.

Cancer Res. 2017 Feb 15;77(4):1035-1046. doi: 10.1158/0008-5472.CAN-16-2621. Epub 2017 Jan 12.

8.

Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation.

Dutta A, Le Magnen C, Mitrofanova A, Ouyang X, Califano A, Abate-Shen C.

Science. 2016 Jun 24;352(6293):1576-80. doi: 10.1126/science.aad9512.

9.

Optimizing mouse models for precision cancer prevention.

Le Magnen C, Dutta A, Abate-Shen C.

Nat Rev Cancer. 2016 Mar;16(3):187-96. doi: 10.1038/nrc.2016.1. Epub 2016 Feb 19. Review.

10.

Atg7 cooperates with Pten loss to drive prostate cancer tumor growth.

Santanam U, Banach-Petrosky W, Abate-Shen C, Shen MM, White E, DiPaola RS.

Genes Dev. 2016 Feb 15;30(4):399-407. doi: 10.1101/gad.274134.115.

11.

Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models.

Mitrofanova A, Aytes A, Zou M, Shen MM, Abate-Shen C, Califano A.

Cell Rep. 2015 Sep 29;12(12):2060-71. doi: 10.1016/j.celrep.2015.08.051. Epub 2015 Sep 17.

12.

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE.

Cancer Cell. 2015 Jul 13;28(1):97-113. doi: 10.1016/j.ccell.2015.06.004.

13.

Modelling bladder cancer in mice: opportunities and challenges.

Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C.

Nat Rev Cancer. 2015 Jan;15(1):42-54. doi: 10.1038/nrc3858. Review.

14.

Analyses of tumor-suppressor genes in germline mouse models of cancer.

Wang J, Abate-Shen C.

Cold Spring Harb Protoc. 2014 Aug 1;2014(8):807-12. doi: 10.1101/pdb.top069773.

15.

Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.

Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM, Califano A, Abate-Shen C.

Cancer Cell. 2014 May 12;25(5):638-651. doi: 10.1016/j.ccr.2014.03.017.

16.

Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials.

Abate-Shen C, Pandolfi PP.

Cold Spring Harb Protoc. 2013 Nov 1;2013(11). pii: pdb.top078774. doi: 10.1101/pdb.top078774.

17.

AACR Cancer Progress Report 2013.

AACR Cancer Progress Report Writing Committee, Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, Reed JC, Weiner GJ.

Clin Cancer Res. 2013 Oct 15;19(20 Suppl):S4-98. doi: 10.1158/1078-0432.CCR-13-2107. Epub 2013 Sep 16. No abstract available.

18.

A molecular signature predictive of indolent prostate cancer.

Irshad S, Bansal M, Castillo-Martin M, Zheng T, Aytes A, Wenske S, Le Magnen C, Guarnieri P, Sumazin P, Benson MC, Shen MM, Califano A, Abate-Shen C.

Sci Transl Med. 2013 Sep 11;5(202):202ra122. doi: 10.1126/scitranslmed.3006408. Erratum in: Sci Transl Med. 2013 Sep 18;5(203):203er9.

19.

ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.

Aytes A, Mitrofanova A, Kinkade CW, Lefebvre C, Lei M, Phelan V, LeKaye HC, Koutcher JA, Cardiff RD, Califano A, Shen MM, Abate-Shen C.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):E3506-15. doi: 10.1073/pnas.1303558110. Epub 2013 Aug 5.

20.

ARF regulates the stability of p16 protein via REGγ-dependent proteasome degradation.

Kobayashi T, Wang J, Al-Ahmadie H, Abate-Shen C.

Mol Cancer Res. 2013 Aug;11(8):828-33. doi: 10.1158/1541-7786.MCR-13-0207. Epub 2013 Jul 1.

21.

Canonical Wnt signaling regulates Nkx3.1 expression and luminal epithelial differentiation during prostate organogenesis.

Kruithof-de Julio M, Shibata M, Desai N, Reynon M, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM.

Dev Dyn. 2013 Oct;242(10):1160-71. doi: 10.1002/dvdy.24008. Epub 2013 Jul 29.

22.

Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.

Delto JC, Kobayashi T, Benson M, McKiernan J, Abate-Shen C.

Oncotarget. 2013 Feb;4(2):269-76.

23.

ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Jin F, Irshad S, Yu W, Belakavadi M, Chekmareva M, Ittmann MM, Abate-Shen C, Fondell JD.

Mol Cancer Res. 2013 Jul;11(7):736-47. doi: 10.1158/1541-7786.MCR-12-0618. Epub 2013 Mar 28.

24.

Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity.

Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A, Shen MM.

Nat Cell Biol. 2013 Mar;15(3):274-83. doi: 10.1038/ncb2697. Epub 2013 Feb 24.

25.

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer.

Floc'h N, Abate-Shen C.

Oncotarget. 2012 Dec;3(12):1483-4. No abstract available.

26.

Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.

Irshad S, Abate-Shen C.

Cancer Metastasis Rev. 2013 Jun;32(1-2):109-22. doi: 10.1007/s10555-012-9409-1. Review.

27.

B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer.

Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, Califano A, Shen MM, Abate-Shen C.

Cancer Res. 2012 Sep 15;72(18):4765-76. Epub 2012 Jul 25.

28.

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.

Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A, Cardiff RD, Califano A, Shen MM, Abate-Shen C.

Cancer Res. 2012 Sep 1;72(17):4483-93. doi: 10.1158/0008-5472.CAN-12-0283. Epub 2012 Jul 19.

29.

The MSX1 homeoprotein recruits G9a methyltransferase to repressed target genes in myoblast cells.

Wang J, Abate-Shen C.

PLoS One. 2012;7(5):e37647. doi: 10.1371/journal.pone.0037647. Epub 2012 May 22.

30.
31.

The Msx1 Homeoprotein Recruits Polycomb to the Nuclear Periphery during Development.

Wang J, Kumar RM, Biggs VJ, Lee H, Chen Y, Kagey MH, Young RA, Abate-Shen C.

Dev Cell. 2011 Sep 13;21(3):575-88. doi: 10.1016/j.devcel.2011.07.003.

32.

Molecular genetics of prostate cancer: new prospects for old challenges.

Shen MM, Abate-Shen C.

Genes Dev. 2010 Sep 15;24(18):1967-2000. doi: 10.1101/gad.1965810. Review.

33.

Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin.

Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM.

Urology. 2010 Nov;76(5):1240-4. doi: 10.1016/j.urology.2010.03.059.

PMID:
20627287
34.

Mouse models of human bladder cancer as a tool for drug discovery.

Seager C, Puzio-Kuter AM, Cordon-Cardo C, McKiernan J, Abate-Shen C.

Curr Protoc Pharmacol. 2010 Jun;Chapter 14:Unit14.14. doi: 10.1002/0471141755.ph1414s49.

35.

Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.

Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, Abate-Shen C.

Cancer Prev Res (Phila). 2009 Dec;2(12):1008-14. doi: 10.1158/1940-6207.CAPR-09-0169. Epub 2009 Dec 1.

36.

A luminal epithelial stem cell that is a cell of origin for prostate cancer.

Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM.

Nature. 2009 Sep 24;461(7263):495-500. doi: 10.1038/nature08361. Epub 2009 Sep 9.

37.

Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.

Couto SS, Cao M, Duarte PC, Banach-Petrosky W, Wang S, Romanienko P, Wu H, Cardiff RD, Abate-Shen C, Cunha GR.

Differentiation. 2009 Jan;77(1):103-11. doi: 10.1016/j.diff.2008.09.010. Epub 2008 Oct 16.

38.

Inactivation of p53 and Pten promotes invasive bladder cancer.

Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C, Abate-Shen C.

Genes Dev. 2009 Mar 15;23(6):675-80. doi: 10.1101/gad.1772909. Epub 2009 Mar 4.

39.

Diagnostics: The prostate-cancer metabolome.

Abate-Shen C, Shen MM.

Nature. 2009 Feb 12;457(7231):799-800. doi: 10.1038/457799a. No abstract available.

PMID:
19212391
40.

Progenitor cells for the prostate epithelium: roles in development, regeneration, and cancer.

Shen MM, Wang X, Economides KD, Walker D, Abate-Shen C.

Cold Spring Harb Symp Quant Biol. 2008;73:529-38. doi: 10.1101/sqb.2008.73.050. Epub 2009 Jan 15. Review.

PMID:
19150960
41.

The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges.

Abate-Shen C, Brown PH, Colburn NH, Gerner EW, Green JE, Lipkin M, Nelson WG, Threadgill D.

Cancer Prev Res (Phila). 2008 Aug;1(3):161-6. doi: 10.1158/1940-6207.CAPR-08-0076. Review.

42.

BRAF activation initiates but does not maintain invasive prostate adenocarcinoma.

Jeong JH, Wang Z, Guimaraes AS, Ouyang X, Figueiredo JL, Ding Z, Jiang S, Guney I, Kang GH, Shin E, Hahn WC, Loda MF, Abate-Shen C, Weissleder R, Chin L.

PLoS One. 2008;3(12):e3949. doi: 10.1371/journal.pone.0003949. Epub 2008 Dec 16.

43.

Mouse Fem1b interacts with the Nkx3.1 homeoprotein and is required for proper male secondary sexual development.

Wang X, Desai N, Hu YP, Price SM, Abate-Shen C, Shen MM.

Dev Dyn. 2008 Oct;237(10):2963-72. doi: 10.1002/dvdy.21694.

44.

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C.

J Clin Invest. 2008 Sep;118(9):3051-64. doi: 10.1172/JCI34764.

45.

Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis.

Abate-Shen C, Shen MM, Gelmann E.

Differentiation. 2008 Jul;76(6):717-27. doi: 10.1111/j.1432-0436.2008.00292.x. Epub 2008 Jun 28. Review.

46.

Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer.

Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, Reuter VE, Scardino PT, Shen MM, Aronow BJ, Vickers AJ, Gerald WL, Abate-Shen C.

Cancer Res. 2008 Apr 1;68(7):2132-44. doi: 10.1158/0008-5472.CAN-07-6055.

47.

The current state of preclinical prostate cancer animal models.

Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL.

Prostate. 2008 May 1;68(6):629-39. doi: 10.1002/pros.20726.

48.
49.

Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.

Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, Quinn J, Aronow BJ, Abate-Shen C.

Cancer Res. 2007 Oct 1;67(19):9089-96.

50.

Pten inactivation and the emergence of androgen-independent prostate cancer.

Shen MM, Abate-Shen C.

Cancer Res. 2007 Jul 15;67(14):6535-8. Review.

Supplemental Content

Loading ...
Support Center